Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Is Inogen Ingn Stock A Market Leader Price At 6.39 Up 0.95 20260328 Can Stonex Group Snex Stock Recover Now Price At 84.24 Down 0.14 20260406 Will Duff Phelps Dpg Stock Outperform S P 500 Price At 14.75 Up 0.55 20260406 Is Olema Pharmaceuticals Olma Stock Ready To Move Price At 15.16 Up 0.70 20260406 BFLY Butterfly beats Q1 estimates by 246 yet shares fall 19 on outlook concerns Scholastic Corporation SCHL Stock Downside Risk Weakens 20260415 ADPT Adaptive Biotechnologies Corporation Q4 2025 narrower than expected loss lifts investor sentiment shares rise 277 percent Moving MITQ Stock Warning Signs Under Pressure 20260415 FTEK Fuel Tech shares climb modestly after Q4 2025 earnings notching 61 percent year over year revenue growth First Solar FSLR Stock Retail Sales 018 20260420 Is Republic RJET stock attracting cautious sentiment 404 20260420 Media Distressed Asset Transaction Analysis The Onion Infowars Acquisition Proposal NRSN NeuroSense Therapeutics Q2 loss narrows 69 more than expected but investors await pipeline catalyst update USChina Trade Discussions Return to Spotlight at APEC Economic Leaders Meeting Standard Chartered to Cut Over 15 of Corporate Functions Roles in Pursuit of Higher Returns Yardeni Suggests Fed Could Raise Rates in July to Counter Bond Vigilantes Amid Warsh Transition Should You Roll a 60000 State Pension into a Roth TSP Key Considerations for Federal Employees Microsofts GitHub Faces AI Coding Race Challenges Amid Outages and Competition Semtech Reports Q1 Revenue Growth to 291 Million and Net Income of 266 Million PROG Holdings Q1 2026 Earnings Massive EPS Beat Drives Investor Caution Despite Strong Performance ASR Q1 2026 Earnings EPS Misses Estimates by 153 Stock Declines Barings BDC Inc BBDC Q1 2026 Earnings EPS Misses Estimates Amid Stable Market Conditions NB Q1 2026 Earnings Surprise Profit Highlights Cost Discipline at PreRevenue Developer Beam Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Expense Discipline